Company intelligence
LB Pharmaceuticals Inc
Developing novel therapies for neuropsychiatric diseases
Biotechnology Research
56 employees
Founded 2015
5 public signals
About LB Pharmaceuticals Inc
LB Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of schizophrenia. Our lead drug candidate is a second-generation antipsychotic and a potential first-in-class benzamide to enter the U.S. market. With robust clinical development underway and a focus on long-term patient outcomes, we aim to set a new standard of care for neuropsychiatric conditions.
Verified activity
Signals from LB Pharmaceuticals Inc
5 published signals
Products & Services
LB Pharmaceuticals Inc is developing LB-102, a novel once-daily orally administered investigational small molecule for schizophrenia, bipolar depression, major depressive disorder, and other brain disorders.
Reported by LB Pharmaceuticals Inc
People
LB Pharmaceuticals Inc welcomed Joe to the team as part of scaling operations.
Reported by Ellen Rose
People
LB Pharmaceuticals Inc hired Joe on the team
Reported by Heather Turner
Presence & Recognition
LB Pharmaceuticals Inc will have a presence at multiple investor conferences in September, including meetings at the Wells Fargo 21st Annual Healthcare Conference, a virtual corporate presentation and investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference, and a virtual fireside chat featuring CEO Heather Turner at the TD Cowen 6th Annual Novel Mechanisms Neuropsychiatry Summit.
Reported by LB Pharmaceuticals Inc
People
LB Pharmaceuticals Inc welcomed Joe Miller as Chief Financial Officer.
Reported by LB Pharmaceuticals Inc